Aptose Biosciences completes acquisition by Hanmi Pharmaceutical for C$2.41 per share.
Aptose Biosciences announced the closing of the acquisition by Hanmi Pharmaceutical, delisting shares on July 3. Shareholders received C$2.41 per share, representing a 28% premium over the prior 30-day VWAP.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day